中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 10
Oct.  2016

Clinical effect of albumin-bound paclitaxel in treatment of advanced primary liver cancer

DOI: 10.3969/j.issn.1001-5256.2016.10.017
  • Received Date: 2016-05-23
  • Published Date: 2016-10-20
  • Objective To investigate the clinical effect and safety of albumin-bound paclitaxel( Nab-P) as the first-line treatment for advanced primary liver cancer. Methods A retrospective analysis was performed for the clinical data of 23 patients with advanced primary liver cancer who were admitted to the Department of Medical Oncology in Chinese PLA General Hospital from May 2014 to December 2015.According to the treatment regimen,these patients were divided into observation group and control group. The 12 patients in the observation group were treated with Nab-P,among whom 5 were treated with Nab-P combined with tegafur,gimeracil and oteracil,5 were treated with Nab-P combined with capecitabine,and 2 were treated with Nab-P alone; the 11 patients in the control group were treated with gemcitabine combined with oxaliplatin. One cycle of the treatment was 21 days for each treatment regimen; therapeutic effect was evaluated every2 cycles,and adverse events were evaluated every cycle. The chi-square test or the Fisher's exact test was used for comparison of categorical data between groups,the Kaplan-Meier survival curves were used to analyze progression-free survival,and the log-rank test was used to compare survival rates between groups. Results All the patients were eligible for evaluation of clinical outcome and adverse events.In the observation group,2 patients achieved partial remission,7 had a stable disease,and 3 had a progressive disease; in the control group,2 achieved partial remission,5 had a stable disease,and 4 had a progressive disease. There was no significant difference in disease control rate between the two groups( 75% vs 64%,χ2= 0. 350,P > 0. 05). There was also no significant difference in the median progression-free survival between the two groups [5. 1( 2. 7-6. 7) months vs 4. 3( 2. 5-5. 4) months,χ2= 0. 647,P > 0. 05]. As for adverse events,no patient experienced serious adverse events,and there were significant differences in the incidence rates of platelet toxicity and increased aspartate aminotransferase between the two groups( χ2= 5. 490 and 6. 135,P = 0. 036 and 0. 027). Conclusion In the treatment of advanced primary liver cancer,the medication based on Nab-P shows a good clinical effect and tolerable toxic and side effects; however,due to the small sample size in this study,the clinical studies with a large sample size are needed.

     

  • [1]CHEN WQ,ZHENG RS,BAADE PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
    [2]ROH Y,DAVID KC,SONG S,et al.The prognosis and treatment outcomes of patients with recurrent hepatocellular carcinoma after liver transplantation[J].Clin Transplant,2014,28(1):141-148.
    [3]BRUIX J,SHERMAN M,LLOVET JM,et al.EASL panel of experts on HCC clinical management of hepatocellular carcinoma:conclusions of the Barcelona-2000 EASL conference[J].J Hepatol,2001,35(3):421-430.
    [4]YE SL,CHEN RX.Comments on management of hepatocellular carcinoma:an update[J].Chin J Hepatol,2011,19(4):251-254.(in Chinese)叶胜龙,陈荣新.《肝细胞癌临床指南更新》解读[J].中华肝脏病杂志,2011,19(4):251-254.
    [5]GONG S,SUN JM,TIAN LL,et al.Research progress of the anti-tumor effect of alkaloids of natural medicine[J].Jilin J Tradit Chin Med,2014,34(9):927-931.(in Chinese)宫爽,刘佳明,田淋淋,等.天然药物中生物碱类成分抗肿瘤活性[J].吉林中医药,2014,34(9):927-931.
    [6]XIE LL,YANG TJ,ZHANG CP,et al.Clinical progress on nanoparticle albumin-bound paclitaxel[J].J Pharm Res,2014,33(5):289-291.
    [7]LI Z,ZHANG WG,HAN XW.Recent advances in interventional therapy of hepatocellular carcinoma[J].World Chin J Dig,2011,19(3):221-226.(in Chinese)李臻,张文广,韩新巍.原发性肝细胞癌介入治疗的现状与进展[J].世界华人消化杂志,2011,19(3):221-226.
    [8]RAOUL JL,SANGRO B,FOMER A,et al.Evolving strategies for the management of intermediate-stage hepatocellular carcinoma:available evidence and expert opinion on the use of transarterial chemoembo Iization[J].Cancer Treat Rev,2011,37(3):212-220.
    [9]WANG F,QIN SK,HUA HQ,et al.Report of two cases of hepatitis B virus reactivation in primary liver carcinoma patients treated with the FOLFOX chemotherapy regimen[J].Chin J Hepatol,2014,22(3):236-238.(in Chinese)王锋,秦叔逵,华海清,等.FOLFOX4方案治疗晚期肝癌引起乙型肝炎病毒再激活2例报道[J].中华肝脏病杂志,2014,22(3):236-238.
    [10]YI WL,FANG L,LIAO XL,et al.A clinical study of gemcitabine plus oxaliplatin in the treatment of advanced primary liver cancer[J].J Guangxi Med Univ,2014,31(5):756-760.(in Chinese)义维丽,房亮,廖小莉,等.吉西他滨联合奥沙利铂治疗中晚期原发性肝癌的临床疗效和安全性观察[J].广西医科大学学报,2014,31(5):756-760.
    [11]LI HT,LEI YQ,HUANG JH,et al.Study of the efficacy and safety of GEMOX regimen for the patients with advanced primary liver cancer[J].J Clin Exp Med,2014,13(4):274-276.(in Chinese)李海涛,雷叶青,黄劲华,等.吉西他滨联合奥沙利铂治疗晚期原发性肝癌患者的疗效和安全性研究[J].临床和实验医学杂志,2014,13(4):274-276.
    [12]ZHANG SM,ZHANG N.Research progress of hepatocellular carcinoma chemotherapy[J].Chin J New Drugs Clin Rem,2015,34(2):93-98.
    [13]SWET JH,PACHECO HJ,IANNITI DA,et al.A silica-calcium-phosphate nanocomposite drug delivery system for the treatmentof hepatocellular carcinoma:in vivo study[J].J Biomed Mater Res,2014,102(1):190-202.
    [14]WANG L,LI M,ZHANG N.Folate-targeted docetaxel-lipidbased-nanosuspensions for active-targeted cancer therapy[J].Int J Nanomed,2012,7(7):3281-3294.
    [15]ZHOU Q,SUN X,ZENG L,et al.A randomized multicenter phaseⅡclinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma[J].Nanomedicine,2009,5(4):419-423.
    [16]JOHN TA,VOGEL SM,TIRUPPATHI C,et al.Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer[J].Am J Physiol Lung Cell Mol Physiol,2003,184(1):184-196.
    [17]TENERIELLO MG,TSENG PC,CROZIER M,et al.PhaseⅡevaluation of nanopartiele albumin-bound paclitaxel in platinumsensitive patients with recurrent ovarian,peritoneal,or fallopian tube cancer[J].J Clin Oncol,2009,27(9):1426-1431.
    [18] 医療用医薬品:アブラキサン[EB/OL].http://www.kegg.jp/medicus-bin/japic_med?japic_code=00058810
    [19]XU J,LIU ZS,ZHANG ZL.Effects of paclitaxel on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice[J].Wuhan Univ J Med Sci,2005,26(4):449-451.(in Chinese)许俊,刘志苏,张中林.紫杉醇对裸鼠人肝癌血管生成和肿瘤生长、转移的作用[J].武汉大学学报:医学版,2005,26(4):449-451.
    [20]MA YL,QI HY,CAO ZD,et al.Studies on the preparation of docetaxel nano-liposomes and its treatment on liver cancer cells in vivo and in vitro[J].Chin J Biological Pharms,2015,35(6):43-47.(in Chinese)马友龙,祁海艳,曹振东,等.多西紫杉醇纳米脂质体的制备及其对肝癌细胞的体内外治疗研究[J].中国生化药物杂志,2015,35(6):43-47.
    [21]ZHANG T,DUAN RC,ZHANG R.A retrospective analysis of combination of gemcitabine and docetaxel in patients with advanced hepatocellular carcinoma[J].Cancer Res Prevent Treat,2102,39(11):1369-1372.(in Chinese)张彤,段仁慈,张蕊.吉西他滨联合多西紫杉醇方案治疗晚期肝癌的临床观察[J].肿瘤防治研究,2102,39(11):1369-1372.
  • Relative Articles

    [1]Shuaixia FENG, Ying XU, Han HAN. Role and potential significance of peroxisome proliferator-activated receptors in liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(7): 1747-1753. doi: 10.3969/j.issn.1001-5256.2023.07.034
    [2]Jiahe ZHAO, Xinyu MA, Jingya XU, Tingting DUAN, Chunlei ZHANG, Baolong LI. Research advances in related factors for autophagy in the regulation of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(7): 1713-1717. doi: 10.3969/j.issn.1001-5256.2021.07.050
    [3]Li WenMi, Wang Nan, Bian Qian, Huang Qian, Li JingTao, Wei HaiLiang, Yan ShuGuang. Role of liver X receptor in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(10): 2349-2352. doi: 10.3969/j.issn.1001-5256.2020.10.041
    [4]Chen YiYan, Lu Yan. Application of nuclear receptor in pathogenesis research and drug development for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1221-1223. doi: 10.3969/j.issn.1001-5256.2020.06.006
    [5]Ren Shan, Du XiaoFei, Huang YunLi, Huang ChunYang, Zhang XiaoDan, Dan Jing, Chen XinYue. Serum interferon-gamma-induced protein-10 level and gene polymorphism in patients with drug-induced liver injury accompanied by autoimmune phenomena[J]. Journal of Clinical Hepatology, 2020, 36(3): 602-607. doi: 10.3969/j.issn.1001-5256.2020.03.026
    [6]A RuHan, Jia HaiYan, Ding YanHua, Niu JunQi. Research advances in nonalcoholic fatty liver disease in lean individuals[J]. Journal of Clinical Hepatology, 2020, 36(5): 1154-1159. doi: 10.3969/j.issn.1001-5256.2020.05.046
    [7]Chu PeiLing, Wang Qi, Guo XiaoQing, Liu JinChun. Association between chemokines and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(7): 1626-1628. doi: 10.3969/j.issn.1001-5256.2019.07.044
    [8]Ou WeiJie, Lin YeHong, Zhou Qing, Shang TianYu, Lin Su, Zhu YueYong. Association of vitamin D-related gene polymorphisms with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(6): 1308-1312. doi: 10.3969/j.issn.1001-5256.2019.06.025
    [9]Liu Qun, Luan GuiPing, Gao Hui, Zhao BenTian, Du ShuiXian, Liu ShouSheng, Xin YongNing. Association of TRIB1 rs2954029 single nucleotide polymorphism with the risk of nonalcoholic fatty liver disease and coronary heart disease[J]. Journal of Clinical Hepatology, 2019, 35(6): 1330-1336. doi: 10.3969/j.issn.1001-5256.2019.06.030
    [10]Zhou Fan, Peng JunWei, Fan FuGang, Jiang YuanYe, Cao Qin. Interrelation between autophagy and oxidative stress in pathogenesis of nonalcoholic fatty liver[J]. Journal of Clinical Hepatology, 2018, 34(8): 1805-1808. doi: 10.3969/j.issn.1001-5256.2018.08.048
    [12]Liao SongLing, Liu ShouSheng, Wang Cong, Chen LiZhen, Xin YongNing, Xuan ShiYing. Association between MBOAT7 rs641738 polymorphism and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(10): 2169-2174. doi: 10.3969/j.issn.1001-5256.2018.10.021
    [13]Yue HaiYan, Liu ShouSheng, Wang Cong, Gu JiuLian, Xin YongNing, Xuan ShiYing. Association between single nucleotide polymorphism of low-density lipoprotein receptor and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(9): 1929-1935. doi: 10.3969/j.issn.1001-5256.2018.09.021
    [14]Zhang Hua, He DeHua, Li GuiZhong. Association between single nucleotide polymorphism of microRNA-146a and recurrence after liver cancer surgery[J]. Journal of Clinical Hepatology, 2016, 32(5): 904-907. doi: 10.3969/j.issn.1001-5256.2016.05.018
    [15]Liu Yang, Jiang Man, Chen LiZhen, Du ShuiXian, Xin YongNing, Xuan ShiYing. Association between AGTR1 gene polymorphism and risk of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2015, 31(7): 1082-1087. doi: 10.3969/j.issn.1001-5256.2015.07.020
    [16]Xu Xin, Jiang Man, Li JiangWen, Dong QuanYong, Lin ZhongHua, Chu LeiLei, Xin YongNing, Xuan ShiYing. Association between PPARγ gene rs3856806 polymorphism and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2015, 31(7): 1088-1091. doi: 10.3969/j.issn.1001-5256.2015.07.021
    [17]Xin Xuan, Yan HongZhu, Li WeiQing, Yu HongYu. Studies on PPAR α and γ participating in progression of liver fibrosis by regulating ACSL1[J]. Journal of Clinical Hepatology, 2014, 30(7): 700-702. doi: 10.3969/j.issn.1001-5256.2014.07.034
    [18]Xin Xuan, Yan HongZhu, Li WeiQing, Yu HongYu. Studies on PPAR α and γ participating in progression of liver fibrosis by regulating ACSL1[J]. Journal of Clinical Hepatology, 2014, 30(8): 833-835. doi: 10.3969/j.issn.1001-5256.2014.08.038
    [19]Niu TongHong, Zhang Mei, Jiang Man, Xin YongNing, Xuan ShiYing. Research advances in gene polymorphisms in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2013, 29(12): 947-951. doi: 10.3969/j.issn.1001-5256.2013.12.020
    [20]Shen Bo, Nie YuQiang. Peroxisome proliferator- activated receptor gamma inhibits liver cancer proliferation and metastasis in vitro[J]. Journal of Clinical Hepatology, 2013, 29(9): 702-706. doi: 10.3969/j.issn.1001-5256.2013.09.018
  • Cited by

    Periodical cited type(7)

    1. 季丹. 凝血酶原时间与血小板检测对肝硬化患者诊断的临床意义. 人人健康. 2020(08): 263 .
    2. 何搏,张春清. 卡维地洛治疗肝硬化门静脉高压症的作用机制及应用现状. 临床肝胆病杂志. 2019(02): 399-401 . 本站查看
    3. 文政伟,李秋兰,何均辉. 慢性乙型肝炎患者抗病毒治疗后肝纤维化动态变化的定性评估. 中国肝脏病杂志(电子版). 2019(01): 77-80 .
    4. 曹海丹,黄寅,罗晓蓉,吴县斌. 卡维地洛与普萘洛尔治疗肝硬化门静脉高压的临床疗效及不良反应的对照研究. 北方药学. 2019(11): 138-140 .
    5. 高云飞,高凤成,李清峰,马强,邢通潮,杜婷婷. 原发性肝细胞癌患者TACE治疗前后血清血小板源性生长因子-BB水平变化及其临床意义. 现代检验医学杂志. 2019(06): 73-76 .
    6. 由淑萍,张石蕾,赵军,马龙,刘涛. 毛蕊花糖苷对血小板衍生生长因子BB处理后大鼠肝星状细胞的影响. 癌变·畸变·突变. 2018(06): 473-478 .
    7. 汤伟伟,何永文. PDGF-BB/PDGFR-β与肿瘤发生发展的研究进展. 临床与病理杂志. 2017(11): 2457-2462 .

    Other cited types(7)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 5.2 %FULLTEXT: 5.2 %META: 91.1 %META: 91.1 %PDF: 3.7 %PDF: 3.7 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 3.5 %其他: 3.5 %其他: 0.5 %其他: 0.5 %China: 0.6 %China: 0.6 %India: 0.2 %India: 0.2 %Macau: 0.2 %Macau: 0.2 %Russian Federation: 0.2 %Russian Federation: 0.2 %Singapore: 0.2 %Singapore: 0.2 %上海: 5.2 %上海: 5.2 %东莞: 0.3 %东莞: 0.3 %中卫: 1.0 %中卫: 1.0 %临沂: 0.2 %临沂: 0.2 %兰州: 0.3 %兰州: 0.3 %北京: 13.2 %北京: 13.2 %北方邦: 0.5 %北方邦: 0.5 %南京: 0.2 %南京: 0.2 %南宁: 0.3 %南宁: 0.3 %台北: 0.2 %台北: 0.2 %合肥: 0.2 %合肥: 0.2 %吉林: 0.6 %吉林: 0.6 %周口: 0.2 %周口: 0.2 %呼和浩特: 0.3 %呼和浩特: 0.3 %奥克兰: 0.2 %奥克兰: 0.2 %宿州: 0.2 %宿州: 0.2 %常德: 0.2 %常德: 0.2 %广州: 0.5 %广州: 0.5 %张家口: 1.4 %张家口: 1.4 %徐州: 0.2 %徐州: 0.2 %成都: 0.3 %成都: 0.3 %无锡: 0.8 %无锡: 0.8 %昆明: 0.8 %昆明: 0.8 %朝阳: 0.3 %朝阳: 0.3 %杭州: 1.6 %杭州: 1.6 %沈阳: 0.2 %沈阳: 0.2 %洛杉矶: 0.2 %洛杉矶: 0.2 %洛阳: 0.3 %洛阳: 0.3 %济南: 0.2 %济南: 0.2 %温州: 0.2 %温州: 0.2 %石家庄: 0.6 %石家庄: 0.6 %福州: 0.8 %福州: 0.8 %绍兴: 0.2 %绍兴: 0.2 %绥化: 0.2 %绥化: 0.2 %绵阳: 0.2 %绵阳: 0.2 %芒廷维尤: 35.4 %芒廷维尤: 35.4 %芝加哥: 0.2 %芝加哥: 0.2 %苏州: 0.8 %苏州: 0.8 %莫斯科: 0.8 %莫斯科: 0.8 %菏泽: 0.2 %菏泽: 0.2 %衡水: 0.2 %衡水: 0.2 %西宁: 20.5 %西宁: 20.5 %西安: 1.1 %西安: 1.1 %郑州: 0.5 %郑州: 0.5 %都伯林: 0.2 %都伯林: 0.2 %鄂州: 0.2 %鄂州: 0.2 %重庆: 0.3 %重庆: 0.3 %长春: 0.5 %长春: 0.5 %长沙: 0.8 %长沙: 0.8 %长治: 0.2 %长治: 0.2 %阳泉: 0.2 %阳泉: 0.2 %青岛: 0.6 %青岛: 0.6 %马鞍山: 0.2 %马鞍山: 0.2 %龙岩: 0.2 %龙岩: 0.2 %其他其他ChinaIndiaMacauRussian FederationSingapore上海东莞中卫临沂兰州北京北方邦南京南宁台北合肥吉林周口呼和浩特奥克兰宿州常德广州张家口徐州成都无锡昆明朝阳杭州沈阳洛杉矶洛阳济南温州石家庄福州绍兴绥化绵阳芒廷维尤芝加哥苏州莫斯科菏泽衡水西宁西安郑州都伯林鄂州重庆长春长沙长治阳泉青岛马鞍山龙岩

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2715) PDF downloads(433) Cited by(14)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return